Howard Hughes Medical Institute’s Biogen BIIB Stock Holding History

Howard Hughes Medical Institute’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-31	Closed	-$5.46K	–	86
2025 Q4	$5.46K	Hold	31	–	–	﹤0.01%	323
2025 Q3	$4.34K	Hold	31	–	–	﹤0.01%	368
2025 Q2	$3.89K	Buy	+31	New	+$3.86K	﹤0.01%	379
2017 Q3	–	Sell	-1,150	Closed	-$312K	–	43
2017 Q2	$312K	Sell	1,150 -2,247	-66%	-$594K	0.06%	110
2017 Q1	$929K	Sell	3,397 -332	-9%	-$93.9K	0.17%	74
2016 Q4	$1.06M	Sell	3,729 -792	-18%	-$235K	0.24%	69
2016 Q3	$1.42M	Buy	4,521 +4,171	+1,192%	+$1.24M	0.36%	58
2016 Q2	$85K	Sell	350 -167	-32%	-$44K	0.03%	134
2016 Q1	$135K	Buy	+517	New	+$137K	0.03%	126
2015 Q4	–	Sell	-696	Closed	-$203K	–	171
2015 Q3	$203K	Buy	+696	New	+$230K	0.04%	120
2014 Q3	–	Sell	-143	Closed	-$45K	–	180
2014 Q2	$45K	Buy	+143	New	+$43K	0.01%	145

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Howard Hughes Medical Institute's BIIB Position: Q1 2026 in Review

Howard Hughes Medical Institute sold out of Biogen (BIIB) in Q1 2026, closing a stake of 31 shares — an estimated $5.46K sold.

Howard Hughes Medical Institute first reported a position in BIIB in Q2 2014 and held it in 11 quarters. The position peaked at $1.42M in Q3 2016. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Howard Hughes Medical Institute reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
Howard Hughes Medical Institute sold 31 Biogen shares in Q1 2026, an estimated $5.46K.
Howard Hughes Medical Institute first reported a position in Biogen in Q2 2014 and held it in 11 quarters.
Howard Hughes Medical Institute's Biogen position peaked at $1.42M in Q3 2016.
1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Howard Hughes Medical Institute's 13F filing for Q1 2026, filed 15 May 2026.